Denali Therapeutics. has been granted a patent for various crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, detailing their preparation processes and potential pharmaceutical applications. GlobalData’s report on Denali Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Denali Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Denali Therapeutics's grant share as of June 2024 was 19%. Grant share is based on the ratio of number of grants to total number of patents.
Crystalline forms of a specific pharmaceutical compound
The granted patent US11999750B2 encompasses various crystalline forms of the compound (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, specifically identifying six distinct forms labeled A through F. Each form is characterized by unique X-ray powder diffraction (XRPD) patterns and differential scanning calorimetry (DSC) profiles, which provide critical data for their identification and potential applications. For instance, Form A exhibits an XRPD pattern with specific peaks at 6.9, 11.5, and 19.4 degrees, while Form B shows peaks at 9.6 and 16.4 degrees. The DSC analysis reveals distinct thermal behaviors for each form, indicating their stability and potential utility in pharmaceutical formulations.
Additionally, the patent outlines a method for treating various diseases and disorders mediated by RIPK1, utilizing an effective amount of the crystalline forms described. The conditions targeted include a wide range of inflammatory and autoimmune diseases, such as Crohn's disease, rheumatoid arthritis, and multiple sclerosis, as well as other serious health issues like myocardial infarction and neurodegenerative diseases. This broad therapeutic application underscores the significance of the crystalline forms in addressing complex medical conditions, potentially offering new avenues for treatment in the pharmaceutical landscape.
To know more about GlobalData’s detailed insights on Denali Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
